Clinics That Treat Hepatitis C and Addiction Together

If you are asking what clinics treat both hepatitis C and addiction together, the answer starts with understanding why that combination of care matters so much. Referral-based split care shows much lower HCV treatment uptake than integrated programs. Program evaluations consistently find that patients handed a referral slip rarely follow through. The two conditions are epidemiologically linked via shared transmission routes, primarily injection drug use. They worsen each other, and separating them into different care tracks often means one never gets addressed at all.

Co-occurring hepatitis C and opioid use disorder is not rare. In one quality improvement study that screened over 5,800 patients with opioid use disorder, more than 27% tested positive for HCV. Among pregnant women with OUD, national data has shown rates running dramatically higher. The overlap is large enough that any addiction clinic not screening for HCV is leaving a significant share of its patients with an undiagnosed, progressing disease. Restoration Recovery is one of a small number of outpatient programs in Southeast Tennessee and North Georgia offering dual-track care, treating both conditions in the same setting without sending patients elsewhere to navigate it alone.

Why Hepatitis C and Opioid Addiction Go Hand in Hand

The Shared Needle Connection

The primary transmission route for hepatitis C in the United States is injection drug use. Sharing needles, syringes, and drug preparation equipment creates direct blood-to-blood contact, which is highly efficient for HCV transmission. People who inject opioids face disproportionate exposure, and the virus spreads rapidly within networks of people who use together.

What makes this particularly dangerous is that most people do not know they have it. HCV is often asymptomatic for years, sometimes decades. People in active addiction rarely access routine bloodwork or primary care. By the time symptoms appear, liver damage can already be advanced. This is precisely why screening at the point of addiction care matters so much: it catches HCV in people who would never otherwise be tested.

The Physical Cost of Untreated Hepatitis C During Recovery

Untreated HCV does not pause while someone is working through addiction recovery. It continues progressing. Inflammation gives way to fibrosis, fibrosis to cirrhosis, and eventually to liver failure or hepatocellular carcinoma. Co-occurring substance use and the barriers to care it creates can allow liver disease to advance unchecked. A person can make real gains in their addiction treatment and still be losing ground medically because the underlying liver disease keeps progressing.

The recovery process gets most of the attention, but the liver is quietly paying the price the entire time if HCV is left alone. Treating addiction without addressing HCV is a partial solution at best, one that leaves a serious, progressing disease in the background.

How Untreated Hepatitis C Makes Recovery Harder

Chronic HCV is associated with higher rates of fatigue, depression, and mental health conditions that complicate sustained recovery. These are not minor inconveniences. They are symptoms that make staying off opioids significantly harder, especially in the early months when motivation and mental clarity matter most. A person fighting exhaustion and low mood while trying to sustain recovery is fighting a two-front battle with only half the support they need.

Retention studies in MAT populations back this up. Patients in medication-assisted treatment who receive concurrent HCV treatment show better treatment retention and lower rates of illicit opioid use than those who do not, with support from trials including ANCHOR and integrated program evaluations. The two conditions genuinely feed each other. One modeling study found that only 22% of patients in simulated offsite-referral scenarios achieved treatment success, compared to 86–89% in integrated onsite treatment. That gap is not subtle.

What Integrated and Co-Located Care Actually Looks Like

Clinics that treat both hepatitis C and addiction together generally operate under one of two models. The first is full co-location: HCV care delivered physically at the same site as MAT, with providers trained in both areas. The second is an opioid treatment program that has added HCV screening and direct-acting antiviral (DAA) prescribing to its existing services, sometimes supported by telemedicine partnerships connecting MAT patients with HCV specialists through their addiction clinic. Both can work. The key variable is whether HCV treatment actually happens, or whether patients get a referral slip and a phone number they will never call.

One development that makes integration more feasible than it used to be: DAA medications have transformed HCV treatment entirely. Cure rates above 95% in 8 to 12 weeks are now standard. There is no contraindication for patients on MAT. The AASLD‑IDSA guidance is explicit: active drug use is not a reason to withhold DAA treatment. The clinical barrier is much lower than most patients assume.

What the Outcomes Data Shows

The evidence across integrated care models is consistent. The ANCHOR study found that 82% of participants with opioid use disorder who received concurrent HCV and buprenorphine treatment achieved sustained virologic response, meaning they were cured. A separate integrated treatment study reported an 87.8% cure rate overall, and 98.5% among those who completed the full course. Patients in integrated programs also stayed in addiction treatment longer, showed better medication adherence, and used fewer illicit opioids compared to those receiving addiction-only care.

Opioid treatment programs using facilitated telemedicine for HCV co-management showed higher cure rates than off-site referrals, with illicit drug use declining significantly among cured participants. Co-location removes friction: fewer appointments, fewer providers, less stigma. When someone does not have to navigate a separate specialist system to treat their HCV, they actually get treated.

What to Look for in a Clinic That Handles Both

Clinical Features That Signal Real Integration

Not every clinic that mentions hepatitis C offers genuine integrated care. A real integrated program screens all patients for HCV at intake, has prescribers trained or credentialed in DAA therapy, and manages both conditions within the same care relationship — not through an offsite referral that most patients will not follow through on, and not as a future consideration once addiction treatment is “complete.” Ask the clinic directly: do you treat hepatitis C here, or do you send patients elsewhere?

That question cuts through vague answers fast. A clinic with real HCV capacity will tell you immediately how they screen, which DAA regimens they use, and how they handle prior authorization. The answer tells you what you need to know.

Why Regional Access and Multi-Site Coverage Matter

In rural and underserved areas, a single-location clinic cannot serve the communities that need integrated care most. Distance, transportation, and scheduling conflicts are real barriers that eliminate patients from care before they ever get started. Restoration Recovery’s four-clinic model, spanning Chattanooga, Cleveland, Soddy-Daisy, and Ringgold, Georgia, is built to reduce exactly those barriers, putting MAT and hepatitis C treatment within reach for patients across Southeast Tennessee and North Georgia without requiring a hospital referral or a specialist wait.

Insurance and Coverage for Integrated HCV Treatment

How TennCare and Medicaid Approach DAA Coverage

Coverage is more accessible than most patients assume. TennCare currently requires prior authorization for DAA treatment but does not impose fibrosis-stage requirements or substance use restrictions as of 2026. Providers document the HCV diagnosis and genotype, and complex cases involving co-infections or prior DAA treatment require specialist involvement. The process is straightforward for most patients. Tennessee has moved in the direction of removing barriers that previously made HCV treatment inaccessible for people in active addiction treatment.

Georgia Medicaid requirements should be confirmed directly with the clinic. State-level rules change, and our billing team will have current information. The broader national trend has been significant: 34 states have removed prior authorization requirements for most HCV patients, and the days of requiring six to twelve months of documented sobriety before approving treatment are largely behind us. If you were denied coverage in the past, the current rules may be different.

Navigating Prior Authorization Without Getting Stuck

Prior authorization is standard for DAA treatment across TennCare, commercial plans, and Medicare. The difference in outcomes often comes down to who handles that process. When HCV care lives inside the same clinic as your addiction treatment, the prior authorization is filed by the team that already has your clinical history on file. They know the forms, the timelines, and the documentation required. Patients navigating a separate referral to an outside HCV specialist face a second PA process with a second provider, and that friction alone is enough to stop most people from completing treatment. For more information about accepted plans, visit our insurance page.

Finding Integrated Care and Taking the Next Step

For anyone in the Chattanooga region asking what clinics treat both hepatitis C and addiction together, Restoration Recovery is one of the few outpatient programs in the area offering integrated care across four locations, accepting TennCare, Georgia Medicaid, Medicare, and most commercial plans, with same-day appointments available at most sites. Same-day access matters here. Waiting weeks to start addiction treatment means weeks of continued exposure to both conditions getting worse together.

Hepatitis C care at Restoration Recovery is available on-site for patients enrolled in medication-assisted treatment (MAT) or our intensive outpatient program (IOP). For the clinical details of how we deliver DAA therapy — screening, labs, treatment course, and what to expect during the 8- to 12-week medication period — see our hepatitis C treatment page.

The Bottom Line

Co-occurring hepatitis C and opioid addiction is common, serious, and very treatable — but only at clinics equipped to handle both. Treating one while ignoring the other is a medical half-measure. The evidence is consistent: patients do better on both fronts when care is integrated, cure rates for HCV are above 95% with modern DAA medications, and coverage barriers have been dropping steadily across the country.

Integrated care models exist and they work. If you are figuring out what clinics treat both hepatitis C and addiction together, the standard is clear: the clinic should screen for HCV at intake, have DAA-trained providers on staff, handle prior authorization internally, and treat both diagnoses as its problem to solve, not the patient’s. You do not have to choose which condition to address first. We do not make you.